Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Twist Bioscience Corporation - Common Stock (NQ:TWST)

36.13 -1.37 (-3.64%)
Streaming Delayed Price Updated: 2:55 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Twist Bioscience Corporation - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Twist Bioscience Announces Proposed Public Offering of Common Stock
From Twist Bioscience Corporation
Via Business Wire
C2i Genomics Partners with Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience, Eleven Therapeutics Create Synthetic Viral RNA Molecules To Develop Antiviral Vaccines, Therapeutics
Twist Bioscience Corp (NASDAQ: TWST) and Eleven Therapeutics have created a replicon tool that could be used for studying viral genome replication, antiviral drug... 
Via Benzinga
Twist Bioscience Clocks ~50% Jump In Q1 Sales, Lifts FY22 Revenue Guidance
Twist Bioscience Corp (NASDAQ: TWST) reported a  
Via Benzinga
Recap: Twist Bioscience Q1 Earnings
  Twist Bioscience (NASDAQ:TWST) reported its Q1 earnings results on Friday, February 4, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Twist Bioscience and Eleven Therapeutics Create Replicon for Development of Antiviral Tools
From Twist Bioscience Corporation
Via Business Wire
The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Twist Bioscience Reports First Quarter 2022 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Earnings Scheduled For February 4, 2022
Companies Reporting Before The Bell • Brookfield Business (NYSE:BBU) is estimated to report earnings for its fourth quarter. 
Via Benzinga
Earnings Outlook For Twist Bioscience
Twist Bioscience (NASDAQ:TWST) is set to give its latest quarterly earnings report on Friday, 2022-02-04. Here's what investors need to know before the announcement. Analysts estimate that Twist... 
Via Benzinga
Abcam Collaborates With Twist Bioscience to Enhance Antibody Discovery for Diagnostic and Research Applications
From Twist Bioscience Corporation
Via Business Wire
The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News
The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower. 
Via Benzinga
Twist Bioscience Releases Inaugural ESG Report Highlighting Achievements and Initiatives in Diversity and Sustainability
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Signs Collaboration with Artisan Bio to Engineer Next Generation Cell Therapeutics
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Report Fiscal 2022 First Quarter Financial Results on Friday, February 4, 2022
From Twist Bioscience Corporation
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to... 
Via Benzinga
Twist Bioscience’s Comprehensive DNA Synthesis Capabilities Expanded as Industry-Leading Enzymatic Synthesis Process Unveiled at Annual J.P. Morgan Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 615 stocks hit new 52-week lows. Noteable 52-Week Lows: Sea (NYSE:SE) is the largest company in terms of market cap to set a new 52-week low this... 
Via Benzinga
Twist Bioscience Creates Custom Whole Exome Target Enrichment Panel for Canine Genomic Research
From Twist Bioscience Corporation
Via Business Wire
Revelar Biotherapeutics and Twist Bioscience Announce RBT-0813 Neutralizes SARS-CoV-2 Omicron (B.1.1.529/BA.1) and Delta (B.1.617.2) Variants
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches 96-Plex Library Prep Kit for Low Pass High Throughput Next-Generation Sequencing
From Twist Bioscience Corporation
Via Business Wire
Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies Against GPCR Targets
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Now Shipping Synthetic RNA Positive Controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 Variant for Development of Accurate Diagnostic Tests
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Launches Circulating Tumor DNA Reference Controls for Development of Liquid Biopsy Assays
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Announces Participation in SRC-SIA Webinar on the Decadal Plan for Semiconductors
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience to Present at Upcoming Virtual Conferences
From Twist Bioscience
Via Business Wire
Why Are Twist Bioscience Shares Plunging Today?
Twist Bioscience Corporation (NASDAQ: TWST) reported a 17% Y/Y increase in its Q4 revenues to $37.95 million, beating the Wall Street estimate of $37.02 million, driven... 
Via Benzinga
Twist Bioscience Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results
From Twist Bioscience Corporation
Via Business Wire
Twist Bioscience Enters into Definitive Agreement to Acquire Abveris, Bolstering Biopharma Capabilities
From Twist Bioscience Corporation
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.